WuXi Discovery Services

Systemic sclerosis (also known as scleroderma) is a chronic autoimmune disease that leads to the buildup of scar tissue in various internal organs, as well as the skin. Fibrosis is a key feature of systemic sclerosis, where uncontrolled production of collagen and other extracellular matrix proteins by fibroblasts leads to excess connective tissue accumulation. This excessive fibrosis disrupts the normal tissue architecture of affected organs, causing dysfunction and potentially leading to organ failure. Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic disease. Our fibrosis model platform offers insights into the pathogenesis of tissue and organ fibrosis, to support the discovery of effective therapies for treating these diseases. Click 👇 to view our models: https://lnkd.in/g_a6-zuJ #Biotech #DrugDiscovery #DrugDevelopment #SSc #Sclerosis #Fibrosis #Fibrotic #Scleroderma

Join WuXi AppTec at Drug Discovery Chemistry (DDC) 2025, taking place April 15–17 in San Diego, California. This premier event brings together experts in medicinal and biophysical chemistry to explore cutting-edge advancements in small molecule drug discovery. At WuXi AppTec, we are committed to supporting innovators with our comprehensive discovery chemistry solutions, accelerating hit identification, lead optimization, and candidate selection. We are also excited to have our experts presenting at DDC 2025: Robert Byrne | April 15, 9:10 AM | Unleashing the Power of Spectral Shift Technology for Ultra-High Throughput Binding Assays Wenji Su | April 15, 12:25 PM | Application of One-Bead-One-Compound (OBOC) DEL in Drug Discovery Guo Weihui | April 16, 2:40 PM | Accelerating Novel Target Hit Discovery with 1536-Well Plate Cell-Based HTS and HTC Direct to Biology Platform Meet us at DDC 2025 to engage with our experts and explore opportunities for collaboration. You can also schedule a dedicated meeting by clicking below: https://lnkd.in/gi2HBHKx #DDC2025 #DrugDiscovery #SmallMolecules #WuXiAppTec #MedChem #Biophysics

Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. In our latest article, WuXi Biology examines the potential of GLP-1 RAs in MASH treatment, exploring their mechanisms of action, clinical benefits, developmental challenges, and evaluation strategies in preclinical MASH models. Click 👇 to view our case study and learn about our platform of liver disease models: https://lnkd.in/gECfTmD9 #Biotech #DrugDiscovery #MASH #NASH #NAFLD #GLP1 #Fibrosis #Cirrhosis

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical need. Although not fully understood, the mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. WuXi Biology has established gastric cancer and breast cancer cell lines that are stably resistant to paclitaxel. We have also established corresponding in vivo tumor models for these cell lines which exhibit significant resistance. In our latest protocol publication, WuXi Biology scientists describe methods for establishing these paclitaxel-resistant tumor models both in vitro and in vivo, and approaches for investigating the underlying mechanisms of resistance. The authors also describe a method to evaluate the potential of combination therapies to overcome paclitaxel resistance in these models. Click 👇 to view the abstract: https://lnkd.in/gjuSQbXt #Biotech #DrugDiscovery #ABCB1 #Cancer #DrugResistance #Paclitaxel #Taxol #Taxane

Join WuXi AppTec at Drug Discovery Chemistry (DDC) 2025, taking place April 15–17 in San Diego, California. This premier event brings together global experts in medicinal and biophysical chemistry to discuss groundbreaking advancements in small molecule drug discovery. At WuXi AppTec, we provide fully integrated discovery biology and chemistry solutions to accelerate hit identification, lead optimization, and candidate selection. From targeted protein degradation to fragment-based drug discovery and covalent inhibitors, we empower researchers to drive the next generation of therapeutics. Visit us at booth #303 to explore how our services can support your research. Our team will be available to discuss innovative solutions for advancing small molecule drug discovery projects. You can also schedule a dedicated meeting by clicking below: https://lnkd.in/gi2HBHKx #DDC2025 #DrugDiscovery #SmallMolecules #WuXiAppTec #MedChem #Biophysics

Menopausal syndrome refers to a series of physiological and psychological symptoms experienced by women during menopause transition, due to the gradual decline in ovarian function, decreased estrogen levels, and endocrine system imbalance. The number of women experiencing menopause globally is increasing year by year, and the proportion of menopausal women in the total population will continue to rise. The Urogenital and Endocrine Disease Platform of WuXi Biology focuses on various women’s health issues, including menopause, and has established multiple models for urogenital and endocrine diseases. These models are expected to provide valuable support for drug development related to women’s health, accelerating the discovery of new drugs, and promoting their faster application in clinical practice. Click 👇 this link to read our latest article: https://lnkd.in/gSvi6pKc #Biotech #DrugDiscovery #Menopause #PCOS #POF #HPOaxis #OvarianFunction

Our latest WuXi Discovery Services newsletter is out now — featuring deep dives into GLP-1 agonists, the resurgence of covalent inhibitors, and other trends shaping the future of early-stage drug discovery. 📩 Read the full newsletter below. #DrugDiscovery #GLP1 #CovalentInhibitors #WuXiDiscoveryServices

Dr. Annette Bakker, CEO of the Children's Tumor Foundation (CTF), has spent the last decade passionately devoted to finding impactful therapies to treat all forms of neurofibromatosis (NF), genetically-driven rare disease-causing tumors to grow on nerves. Under her leadership, CTF has built global, patient-centric research networks that not only benefit NF patients but has broadened awareness of NF. Notably, the Foundation also engaged in 2 novel drug approvals for NF1 and drugs in clinical testing for NF2-SWN, and has been advocating for a blueprint in accelerating rare disease drug development. In our fourth interview of this series, Dr. Bakker shares her insights on the role of patient organizations, key factors for successful partnerships, and her call to action in rare disease drug development: https://lnkd.in/e-xMS8Qa

Muscarinic acetylcholine receptors (mAChRs) are a family of G protein-coupled receptors (GPCRs) that are activated by the neurotransmitter acetylcholine. mAChRs are found in the central and peripheral nervous system and are involved in many functions. Notably, mAChRs are a target for drugs used to treat diseases like Alzheimer's, Parkinson's, and schizophrenia. WuXi AppTec scientists contributed to a recent publication with their partners on the development and optimization of phase-appropriate synthetic technologies to prepare KTX-005, a potent mAChR agonist. This work describes an enabling synthetic strategy toward KTX-005, including a unique thiadiazole ring opening/closing sequence to facilitate both dichlorothiadiazole desymmetrization with butanethiol as well as functionalization of the azabicyclo ring derivative. Click 👇 this link to view the abstract https://lnkd.in/g6NzrJft #DrugDiscovery #mAChR #GPCR #CNS #RCS #DiscoveryChemistry #MedicinalChemistry #AnalyticalChemistry #SyntheticChemistry

The primary treatment option for Chronic Hepatitis B (CHB) currently involves nucleoside analogues, which can suppress viral replication but do not eliminate the virus, thereby requiring lifelong use. There is an urgent need for better, more definitive treatments for CHB, beyond just lifelong medication management. Capsid assembly modulators (CAMs) are considered a significant new approach to manage chronic hepatitis B (HBV) infection, with the potential to achieve better suppression of the virus and increase the chances of a functional cure. WuXi AppTec scientists contributed to a recent publication, describing the discovery and preclinical profile of Aligos Therapeutics’ ALG-000184, a highly soluble prodrug of the potent HBV CAM ALG-001075. This prodrug is currently being explored in multiple clinical trials in HBV-infected subjects where unprecedented reductions in HBV DNA, RNA and other viral antigens have been observed. Click 👇 this link to view the abstract https://lnkd.in/ghkqpe4w #DrugDiscovery #HBV #CHB #CAM #RCS #DiscoveryChemistry #SpecialtyChemistry #MedicinalChemistry #AnalyticalChemistry #SyntheticChemistry